Mitigating the looming vaccine crisis: Production and delivery of plasmid-based vaccines

Critical Reviews in Biotechnology

Volumn 31, Issue 1, 2011, Pages 32-52

  Ongkudon, Clarence M ^a   Ho, Jenny ^a   Danquah, Michael K ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

bioprocess; DNA vaccine; Plasmid DNA; vaccine delivery; vaccine production

Indexed keywords

BIOPROCESSES; DNA VACCINE; PLASMID DNA; VACCINE DELIVERY; VACCINE PRODUCTION;

BIOMOLECULES; DISEASE CONTROL; DNA; NUCLEIC ACIDS; PURIFICATION; VACCINES; VIRUSES;

DISEASES;

ADVAX; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; PLASMID DNA; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN PRESENTING CELL; AVIAN INFLUENZA; BIOPROCESS; CHROMATOGRAPHY; CODON USAGE; CONTROLLED STUDY; CPG ISLAND; DNA PURIFICATION; DRUG DECOMPOSITION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG PURIFICATION; GENE CONSTRUCT; GENE SEQUENCE; GENETIC IMMUNIZATION; GENETIC SELECTION; HEPATITIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INTESTINE LYMPHATIC TISSUE; LYMPHOID TISSUE; MALARIA; MARKER GENE; MEASLES; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; REPLICON; REVIEW; SEROCONVERSION; TRANSCRIPTION INITIATION; VACCINE PRODUCTION;

ANIMALS; BIOTECHNOLOGY; DNA, SUPERHELICAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PLASMIDS; VACCINES, DNA;

AVES; BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79951823662     PISSN: 07388551     EISSN: 15497801     Source Type: Journal    
DOI: 10.3109/07388551.2010.483460     Document Type: Review

References (182)

1. Aihara H, Miyazaki J. 1998. Gene transfer into muscle by electroporati (Pubitemid 28405859)
2. Alpar HO, Somavarapu S, Atuah KN, Bramwell V. 2005. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Delivery Rev 57: 411-430. (Pubitemid 39550968)
3. Ando S, Putnam D, Pack DW, Langer R. 1999. PLGA microspheres containing plasmid DNA: Preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J Pharm Sci 88: 126-130. (Pubitemid 29037379)
4. Anspach FB. 2001. Endotoxin removal by afnity sorbents. J Biochem Biophys Methods 49: 665-681.
5. Arakawa T, Ejima D, Tsumoto K, Ishibashi M, Tokunaga M. 2007. Improved performance of column chromatography by arginine: Dye-afnity chromatography. Protein Expression Purif 52: 410-414. (Pubitemid 46150116)
6. Bailey JE, Ollis D F. 1986. Biochemical Engineering Fundamentals. Singapore: McGraw-Hill.
7. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. 2008. Emerging nanopharmaceuticals. Nanomed Nanotechnol Biol Med 4: 273-282.
8. Bhattacharya S, Bajaj A. 2009. Advances in gene delivery through molecular design of cationic lipids. Chem Commun 4632-4656.
9. Bivas-Benita M, van Meijgaarden KE, Franken K, Junginger HE, Borchard G, Ottenhof THM, Geluk A. 2004. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201- restricted T-cell epitopes of mycobacterium tuberculosis. Vaccine 22: 1609-1615. (Pubitemid 38447207)
10. Bodles-Brakhop AM, Heller R, Draghia-Akli R. 2009. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: Current clinical developments. Mol Ter 17: 585-592.
11. Borchard G. 2001. Chitosans for gene delivery. Adv Drug Deliv Rev 52: 145-150. (Pubitemid 33079170)
12. Boyaka PN, Tafaro A, Fischer R, Fujihashi K, Jirillo E, McGhee JR. 2003. Terapeutic manipulation of the immune system: Enhancement of innate and adaptive mucosal immunity. Curr Pharm Des 9: 1965-1972. (Pubitemid 37010102)
13. Buck ML. 2005. Combination measles, mumps, rubella, and varicella vaccine. Pediatr Pharm 11: 1-5.
14. Bungay HR. 1963. Economic defnition of continuous fermentation goals. Biotechnol Bioeng 5: 1-7.
15. Canonico AE, Conary JT, Meyrick BO, Brigham KL. 1994. Aerosol and intravenous transfection of human alpha-1-antitrypsin gene to lungs of rabbits. Am J Respir Cell Mol Biol 10: 24-29.
16. Carnes AE. 2008. Fermentation Process for Continuous Plasmid DNA Production. U.S. Patent 20080318283.
17. Carnes AE. 2007. Process for Plasmid DNA Fermentation. U.S. Patent 20070254342.
18. Carnes AE, Hodgson CP, Williams JA. 2006. Inducible Escherichia coli fermentation for increased plasmid DNA production. Biotechnol Appl Biochem 45: 155-166. (Pubitemid 44690220)
19. Castagnoli L, Scarpa M, Kokkinidis M, Banner DW, Tsernoglou D, Cesareni G. 1989. Genetic and structural analysis of the ColE 1 Rop (Rom) protein. EMBO J 8: 621-629. (Pubitemid 19274983)
20. Chen W. 1999. Automated High-Yield Fermentation of Plasmid DNA in Escherichia coli. U.S. Patent 5955323.
21. Choi JS, Joo DK, Kim CH, Kim K, Park JS. 2000. Synthesis of a barbell-like triblock copolymer, poly(l-lysine) dendrimer-block-poly(ethylene glycol)-block-poly(l-lysine) dendrimer, and its self-assembly with plasmid DNA. J Am Chem Soc 122: 474-480. (Pubitemid 30075482)
22. Chun KW, Lee JB, Kim SH, Park TG. 2005. Controlled release of plasmid DNA from photo-cross-linked pluronic hydrogels. Biomaterials 26: 3319-3326. (Pubitemid 39647264)
23. Coban C, Ishii KJ, Gursel M, Klinman DM, Kumar N. 2005. Efect of plasmid backbone modifcation by diferent human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol 778: 1-9.
24. Córdoba LT, Bocanegra ARD, Llorente BR, Hernández ES, Echegoyen FB, Borja R, Bejines FR, Morcillo MFC. 2008. Batch culture growth of Chlorella zofngiensis on efuent derived from two-stage anaerobic digestion of two-phase olive mill solid waste. Electr J Biotech 11: 1-8.
25. Corey L. 1999. HIV vaccines. Medscape HIV/AIDS 5: 1-3.
26. Danquah MK, Forde GM. 2007a. Growth medium selection and its economic impact on plasmid DNA production. J Biosci Bioeng 104: 490-497.
27. Danquah MK, Forde GM. 2008a. Large-volume methacrylate monolith for plasmid purifcation: Process engineering approach to synthesis and application. J Chromatogr A 1188: 227-233.
28. Danquah MK, Forde GM. 2008b. Preparation of macroporous methacrylate monolithic material with convective fow properties for bioseparation: Investigating the kinetics of pore formation and hydrodynamic performance. Chem Eng J 140: 593-599.
29. Danquah MK, Forde GM. 2007b. Te suitability of DEAE-Cl active groups on customized poly(GMA-co-EDMA) continuous stationary phase for fast enzyme-free isolation of plasmid DNA. J Chromatogr B 853: 38-46. (Pubitemid 46891334)
30. Danquah MK, Forde GM. 2008c. Development of a pilot-scale bacterial fermentation for plasmid-based biopharmaceutical production using a stoichiometric medium. Biotechnol Bioprocess Eng 13: 1-10.
31. Danquah MK, Ho J, Forde GM. 2007. Performance of R-N(R9)-R99 functionalised poly(glycidyl methacrylate-co-ethylene glycol dimethacrylate) monolithic sorbent for plasmid DNA adsorption. J Sep Sci 30: 2843-2850. (Pubitemid 350238314)
32. de Lima MCP, Simoes S, Pires P, Faneca H, Duzgunes N. 2001. Cationic lipid-DNA complexes in gene delivery: From biophysics to biological applications. Adv Drug Deliv Rev 47: 277-294. (Pubitemid 32324118)
33. de Vries RD, Stittelaar KJ, Osterhaus AD, de Swart RL. 2008. Measles vaccination: New strategies and formulations. Expert Rev Vaccines 7: 1215-1223.
34. Diogo MM, Queiroz JA, Prazeres DMF. 2005. Chromatography of plasmid DNA. J Chromatogr A 1069: 3-22. (Pubitemid 40385093)
35. Dufes C, Uchegbu IF, Schatzlein AG. 2005. Dendrimers in gene delivery. Adv Drug Deliv Rev 57: 2177-2202. (Pubitemid 41759392)
36. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen MC, Otten GR, Ulmer JB, Donnelly JJ, Ott G, McDonald DM. 2000. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 165: 2850-2858. (Pubitemid 30660737)
37. Edwards DA, Hanes J, Caponetti G, Hrkach J, BenJebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. 1997. Large porous particles for pulmonary drug delivery. Science 276: 1868-1871. (Pubitemid 27443665)
38. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL. 1994. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269: 2550-2561. (Pubitemid 24235749)
39. Felgner PL. 1996. Improvements in cationic liposomes for in vivo gene transfer. Hum Gene Ter 7: 1791-1793.
40. Filomena S, Passarinha L, Sousa F, Queiroz JA, Domingues FC. 2009. Infuence of growth conditions on plasmid DNA production. J Microbiol Biotechnol 19: 1408-1414.
41. Freitas SS, Santos AL, Prazeres DMF. 2009. Plasmid purifcation by hydrophobic interaction chromatography using sodium citrate in the mobile phase. Sep Purif Tech 65: 95-104.
42. Fukunaka Y, Iwanaga K, Morimoto K, Kakemi M, Tabata Y. 2002. Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation. J Control Release 80: 333-343. (Pubitemid 34273770)
43. Furuichi K, Katakura Y, Ninomiya K, Shioya S. 2007. Enhancement of 1,4- dihydroxy-2-naphthoic acid production by Propionibacterium freudenreichii ET-3 fed-batch culture. Appl Environ Microbiol 73: 3137-3143. (Pubitemid 46834962)
44. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. 1993. DNA vaccines-Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 90: 11478-11482. (Pubitemid 24008662)
45. Garmory HS, Brown KA, Titball RW. 2003. DNA vaccines: Improving expression of antigens. Genet Vaccines Ter 1: 1-5.
46. Genton B. 2008. Malaria vaccines: A toy for travelers or a tool for eradication? Expert Rev Vaccines 7: 597-611. (Pubitemid 351890331)
47. Ghosh P, Han G, De M, Kim CK, Rotello VM. 2008. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 60: 1307-1315.
48. Glenting J, Wessels S. 2005. Ensuring safety of DNA vaccines. Microb Cell Factories 4: 26-30.
49. Godbey WT, Wu KK, Mikos AG. 2001. Poly(ethylenimine)-mediated gene delivery afects endothelial cell function and viability. Biomaterials 22: 471-480. (Pubitemid 32007852)
50. Gorman CM, Aikawa M, Fox B, Fox E, Lapuz C, Michaud B, Nguyen H, Roche E, Sawa T, WienerKronish JP. 1997. Efcient in vivo delivery of DNA to pulmonary cells using the novel lipid edmpc. Gene Ter 4: 983-992. (Pubitemid 27437725)
51. Goula D, Benoist C, Mantero S, Merlo G, Levi G, Demeneix BA. 1998. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ter 5: 1291-1295. (Pubitemid 28448439)
52. Goya AK, Khatri K, Mishra N, Vyas SP. 2008. New patents on mucosal delivery of vaccines. Expert Opin Ter Pat 18: 1271-1288.
53. Gupta AK, Gupta M. 2005. Cytotoxicity suppression and cellular uptake enhancement of surface modifed magnetic nanoparticles. Biomaterials 26: 1565-1573. (Pubitemid 39441388)
54. Han Y, Forde GM. 2008. Single step purifcation of plasmid DNA using peptide ligand afnity chromatography. J Chromatogr B 874: 21-26.
55. Harrison RG, Todd PW, Rudge SR, Petrides D. 2002. Bioseparations Science and Engineering. Oxford University Press, UK.
56. Hartmann G, Krieg AM. 2000. Mechanism and function of a newly identifed CpG DNA motif in human primary B cells. J Immunol 164: 944-953.
57. Hedley ML, Curley J, Urban R. 1998. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 4: 365-368. (Pubitemid 28144100)
58. Helson R, Olszewska W, Singh M, Megede JZ, Melero JA, Hagan DO, Openshaw PJM. 2008. Polylactide-co-glycolide (plg) microparticles modify the immune response to DNA vaccination. Vaccine 26: 753-761.
59. Henke A. 2000. DNA immunization-A new chance in vaccine research? Med Microbiol Immunol 191: 187-190.
60. Ho J, Wang HT, Forde GM. 2008. Process considerations related to the microencapsulation of plasmid DNA via ultrasonic atomization. Biotechnol Bioeng 101: 172-181.
61. Hofand HEJ, Nagy D, Liu JJ, Spratt K, Lee YL, Danos O, Sullivan SM. 1997. In vivo gene transfer by intravenous administration of stable cationic lipid DNA complex. Pharm Res 14: 742-749. (Pubitemid 27281668)
62. Hofand HEJ, Shephard L, Sullivan SM. 1996. Formation of stable cationic lipid/DNA complexes for gene transfer. Proc Natl Acad Sci USA 93: 7305-7309. (Pubitemid 26243545)
63. Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. Nat Med 11: S45-S53. (Pubitemid 40562303)
64. http://www.wiley.co.uk/genmed/clinical/.
65. Gene therapy clinical trials worldwide. Wiley.
66. Huang Y, Krasnitz M, Rabadan R, Witten DM, Song Y, Levine AJ, Ho DD, Robins H. 2008. A recoding method to improve the humoral immune response to an HIV DNA vaccine. PLoS ONE 3: 3214-3218.
67. Huber H, Buchinger W, Diewok J, Ganja R, Keller D, Urthaler J, Necina R. 2008. Industrial manufacturing of plasmid DNA:Boehringer's new cGMP production system employs prudent vector design as a backbone. Genet Eng Biotechnol News 28: 4-6.
68. Huth S, Lausier J, Gersting SW, Rudolph C, Plank C, Welsch U, Rosenecker J. 2004. Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med 6: 923-936. (Pubitemid 40228108)
69. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, Nunez-Alonso G, Green AM, Bazzani RP, Sumner-Jones SG, Chan M, Li H, Yew NS, Cheng SH, Boyd AC, Davies JC, Griesenbach U, Porteous DJ, Sheppard DN, Munkonge FM, Alton E, Gill DR. 2008. Cpg-free plasmids confer reduced infammation and sustained pulmonary gene expression. Nat Biotechnol 26: 549-551. (Pubitemid 351668040)
70. Jones DH, Corris S, McDonald S, Clegg JCS, Farrar GH. 1996. Poly(dl-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Proceedings of the International Meeting on Nucleic Acid Vaccines for the Prevention of Infectious Diseases. Bethesda, MD.
71. Kakizawa Y, Kataoka K. 2002. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 54: 203-222. (Pubitemid 34230442)
72. Kang HC, Lee M, Bae YH. 2005. Polymeric gene carriers. Crit Rev Eukaryot Gene Expr 15: 317-342.
73. Kendall M. 2006. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 24: 4651-4656. (Pubitemid 43776781)
74. Kievit FM, Veiseh O, Bhattarai N, Fang C, Gunn JW, Lee D, Ellenbogen RG, Olson JM, Zhang MQ. 2009. PEI-PEG-chitosan-copolymer-coated iron oxide nanoparticles for safe gene delivery: Synthesis, complexation, and transfection. Adv Func Mater 19: 2244-2251.
75. Kim A, Checkla DM, Dehazya P, Chen WL. 2003. Characterization of DNA-hyaluronan matrix for sustained gene transfer. J Control Release 90: 81-95. (Pubitemid 36588881)
76. Ko HJ, Ko SY, Kim YJ, Lee EG, Cho SN, Kang CY. 2005. Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B. Infect Immun 73: 5666-5674.
77. Kong S, Rock CF, Booth A, Willoughby N, O'Kennedy RD, Relton J, Ward JM, Hoare M, Levy MS. 2008. Large-scale plasmid DNA processing: Evidence that cell harvesting and storage methods afect yield of supercoiled plasmid DNA. Biotechnol Appl Biochem 51: 43-51.
78. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, Neutra MR. 2002. Diferential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: Infuence of the menstrual cycle. J Immunol 169: 566-574. (Pubitemid 34686180)
79. KukowskaLatallo JF, Bielinska AU, Johnson J, Spindler R, Tomalia DA, Baker JR. 1996. Efcient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci USA 93: 4897-4902. (Pubitemid 26163501)
80. Kushibiki T, Tomoshige R, Fukunaka Y, Kakemi M, Tabata Y. 2003. In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with diferent cationization extents. J Control Release 90: 207-216. (Pubitemid 36694964)
81. Kushibiki T, Tomoshige R, Iwanaga K, Kakemi M, Tabata Y. 2006. Controlled release of plasmid DNA from hydrogels prepared from gelatin cationized by diferent amine compounds. J Control Release 112: 249-256. (Pubitemid 44304349)
82. Kutzler MA, Weiner DB. 2008. DNA vaccines: Ready for prime time? Nat Rev Genet 9: 776-788.
83. Lechmann M, Liang TJ. 2000. Vaccine development for hepatitis C. Semin Liver Dis 20: 211-226. (Pubitemid 30618717)
84. Lemmens R, Olsson U, Nyhammar T, Stadler J. 2003. Supercoiled plasmid DNA: Selective purifcation by thiophilic/aromatic adsorption. J Chromatogr B 784: 291-300. (Pubitemid 36044012)
85. Levy MS, O'Kennedy RD, Shamlou PA, Dunnill P. 2000. Biochemical engineering approaches to the challenges of producing pure plasmid DNA. Tibtech 18: 296-304.
86. Li GP, Liu ZG, Liao B, Zhong NS. 2009. Induction of T1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell Mol Immunol 6: 45-50.
87. Li PC, Li D, Zhang LX, Li GP, Wang EK. 2008. Cationic lipid bilayer coated gold nanoparticles-mediated transfection of mammalian cells. Biomaterials 29: 3617-3624.
88. Li S, Tan YD, Viroonchatapan E, Pitt BR, Huang L. 2000. Targeted gene delivery to pulmonary endothelium by anti-pecam antibody. Am J Physiol-Lung Cell Mol Physiol 278: L504-L511. (Pubitemid 30152507)
89. Li ZH, Ning W, Wang JM, Choi A, Lee PY, Tyagi P, Huang L. 2003. Controlled gene delivery system based on thermosensitive biodegradable hydrogel. Pharm Res 20: 884-888. (Pubitemid 36628434)
90. Lindner LH, Brock R, Arndt-Jovin D, Eibl H. 2006. Structural variation of cationic lipids: Minimum requirement for improved oligonucleotide delivery into cells. J Control Release 110: 444-456. (Pubitemid 41827499)
91. Listner K, Bentley L, Okonkowski J, Kistler C, Wnek R, Caparoni A, Junker B, Robinson D, Salmon P, Chartrain M. 2006. Development of a highly productive and scalable plasmid DNA production platform. Biotechnol Prog 22: 1335-1345. (Pubitemid 44568809)
92. Liu F, Qi H, Huang L, Liu D. 1997. Factors controlling the efciency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ter 4: 517-523. (Pubitemid 27352948)
93. Liu L, Zhou X, Liu H, Xiang L, Yuan Z. 2005. CpG motif acts as a 'danger signal' and provides a T helper type 1-biased microenvironment for DNA vaccination. Immunology 115: 223-230. (Pubitemid 40733408)
94. Liu MA. 2003. DNA vaccines: A review. J Intern Med 253: 402-410. (Pubitemid 36418924)
95. Lu DM, Hickey AJ. 2007. Pulmonary vaccine delivery. Exp Rev Vaccines 6: 213-226. (Pubitemid 46607457)
96. Luckay A, Sidhu MK, Kjeken R, Megati S, Siew-Yen C, Roopchand V, Garcia-Hand, D, Abdullah R, Braun R, Montefori DC, Rosati M, Felber BK, Pavlakis GN, Mathiesen I, Israe ZR, Eldridge JH, Egan MA. 2007. Efect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specifc immune responses in rhesus macaques. J Virol 81: 5257-5269. (Pubitemid 46744435)
97. Lungwitz U, Breunig M, Blunk T, Gopferich A. 2005. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60: 247-266. (Pubitemid 40804565)
98. Luo D, Saltzman WM. 2000. Synthetic DNA delivery systems. Nat Biotechnol 18: 33-37. (Pubitemid 30041168)
99. Lynn DM, Langer R. 2000. Degradable poly(beta-amino esters): Synthesis, characterization, and self-assembly with plasmid DNA. J Am Chem Soc 122: 10761-10768.
100. Ma ZY, Guan YP, Liu HZ. 2005. Synthesis of monodisperse nonporous crosslinked poly(glycidyl methacrylate) particles with metal afnity ligands for protein adsorption. Polym Int >54: 1502-1507.
101. MacLaughlin FC, Mumper RJ, Wang JJ, Tagliaferri JM, Gill I, Hinchclife M, Rolland AP. 1998. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release 56: 259-272. (Pubitemid 28511146)
102. Magalhães PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna TC, Pessoa A, Jr. 2007. Methods of endotoxin removal from biological preparations: A review. J Pharm Pharmaceut Sci 10: 388-404. (Pubitemid 350079921)
103. Manoj S, Babiuk LA, Hurk DLS. 2004. Approaches to enhance the efcacy of DNA vaccines. Crit Rev Clin Lab Sci 41: 1-39. (Pubitemid 38299788)
104. Manthorpe M, Cornefertjensen F, Hartikka J, Felgner J, Rundell A, Margalith M, Dwarki V. 1993. Gene-therapy by intramuscular injection of plasmid DNA-Studies on frefy luciferease gene-expression in mice. Hum Gene Ter 4: 419-431. (Pubitemid 24308310)
105. May S, Harries D, Ben-Shaul A. 2000. Te phase behavior of cationic lipid-DNA complexes. Biophys J 78: 1681-1697. (Pubitemid 30183567)
106. McNeil SE, Perrie Y. 2006. Gene delivery using cationic liposomes. Exp Opin Ter Pat 16: 1371-1382. (Pubitemid 44612945)
107. Meacle FJ, Zhang H, Papantoniou I, Ward JM, Titchener-Hooker NJ, Hoare M. 2007. Degradation of supercoiled plasmid DNA within a capillary device. Biotechnol Bioeng 97: 1148-1157. (Pubitemid 47195312)
108. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. 2002. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 8: 415-419. (Pubitemid 34407039)
109. Miyata K, Fukushima S, Nishiyama N, Yamasaki Y, Kataoka K. 2007. Peg-based block catiomers possessing DNA anchoring and endosomal escaping functions to form polyplex micelles with improved stability and high transfection efcacy. J Control Release 122: 252-260. (Pubitemid 47404680)
110. Montgomery DL, Ulmer JB, Donnelly JJ, Liu MA. 1997. DNA vaccines. Pharmacol Ter 74: 195-205. (Pubitemid 27337348)
111. Mutschlechner O, Swoboda H, Gapes JR. 2000. Continuous two-stage ABE-fermentation using Clostridium beijerinckii NRRL B592 operating with a growth rate in the frst stage vessel close to its maximal value. J Mol Microbiol Biotechnol 2: 101-105. (Pubitemid 30125167)
112. Nan XZ, He SW, Hao C, Lin CP. 2005. Efects of medium composition on the production of plasmid DNA vector potentially for human gene therapy. J Zhejiang Univ Sci 6B: 396-400.
113. Nguyen DN, Green JJ, Chan JM, Longer R, Anderson DG. 2009. Polymeric materials for gene delivery and DNA vaccination. Adv Mater 21: 847-867.
114. Nishiyama N, Kataoka K. 2006. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ter 112: 630-648. (Pubitemid 44592613)
115. O'Hagan DT, Singh M, Ulmer JB. 2006. Microparticle-based technologies for vaccines. Methods 40: 10-19. (Pubitemid 44415494)
116. Oishi M, Kataoka K, Nagasaki Y. 2006. Ph-responsive three-layered pegylated polyplex micelle based on a lactosylated abc triblock copolymer as a targetable and endosome-disruptive nonviral gene vector. Bioconjug Chem 17: 677-688. (Pubitemid 43794377)
117. O'Kennedy R, Baldwin C, Moore EK. 2000. Efects of growth medium selection on plasmid DNA production and initial processing steps. J Biotechnol 76: 175-183.
118. Ólafsdóttir G, Svansson V, Ingvarsson S, Marti E, Torsteinsdóttir S. 2008. In vitro analysis of expression vectors for DNA vaccination of horses: Te efect of a Kozak sequence. Acta Vet Scand 50: 1-7.
119. Ongkudon CM, Rahman BA, Aziz AA. 2006. Optimization of critical medium components for the expression of recombinant human transferrin in insect cells baculovirus system. J Teknologi F 45: 19-30.
120. Ongkudon CM, Rahman BA, Aziz AA. 2005. Screening of the Sf900-II SFM insect cell culture medium recombinant baculovirus for the expression of recombinant human transferrin. Proceedings of the 15th MSMBB Scientifc Meeting. Kuala Lumpur, Malaysia.
121. Pan CH, Jimenez GS, Nair N, Wei Q, Adams RJ, Polack FP, Rolland A, Vilalta A, Grifn DE. 2008. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 15: 1214-1221.
122. Panyam J, Labhasetwar V. 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55: 329-347. (Pubitemid 36297053)
123. Park Y-C, Kim S-G, Park K, Lee KH, Seo J-H. 2004. Fed-batch production of d-ribose from sugar mixtures by transketolase-defcient Bacillus subtilis SPK1. Appl Microbiol Biotechnol 66: 297-302. (Pubitemid 40064360)
124. Passarinha LA, Diogo MM, Queiroz JA, Monteiro GA, Fonseca LP, Prazeres DMF. 2006. Production of ColE1 type plasmid by Escherichia coli DH5α cultured under nonselective conditions. J Microbiol Biotechnol 16: 20-24. (Pubitemid 43256972)
125. Patil SD, Rhodes DG, Burgessp DJ. 2005. DNA-based therapeutics and DNA delivery systems: A comprehensive review. AAPS 7: 61-77.
126. Perrie Y, Frederik PM, Gregoriadis G. 2001. Liposome-mediated DNA vaccination: Te efect of vesicle composition. Vaccine 19: 3301-3310. (Pubitemid 32324062)
127. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DF, Haynes JR. 1995. Gene-gun based nucleic-acid immunization- Elicitation of humoral and cytotoxic T-lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13: 1427-1430.
128. Petersen H, Kunath K, Martin AL, Stolnik S, Roberts CJ, Davies MC, Kissel T. 2002. Star-shaped poly(ethylene glycol)-block-polyethylenimine copolymers enhance DNA condensation of low molecular weight polyethylenimines. Biomacromolecules 3: 926-936.
129. Phue J-N, Lee SJ, Trinh L, Shiloach J. 2008. Modifed Escherichia coli B (BL21), a superior producer of plasmid DNA compared with Escherichia coli K (DH5a). Biotechnol Bioeng 101: 831-836.
130. Plank C, Schillinger U, Scherer F, Bergemann C, Remy JS, Krotz F, Anton M, Lausier J, Rosenecker J. 2003. Te magnetofection method: Using magnetic force to enhance gene delivery. Biol Chem 384: 737-747. (Pubitemid 36747935)
131. Pouton CW, Seymour LW. 2001. Key issues in non-viral gene delivery. Adv Drug Deliv Rev 46: 187-203.
132. Prather KJ, Sagar S, Murphy J, Chartrain M. 2003. Industrial scale production of plasmid DNA for vaccine and gene therapy: Plasmid design, production, and purifcation. Enzyme Microb Technol 33: 865-883. (Pubitemid 37412544)
133. Prazeres DMF, Ferreira GNM, Monteiro GA, Cooney CL, Cabral JMS. 1999. Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: Problems and bottlenecks. Tibtech 17: 168-174.
134. Rainczuk A, Scorza T, Spithill TW, Smooker PM. 2004. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria. Infect Immun 72: 5565-5573. (Pubitemid 39303664)
135. Remaut E, Tsao H, Fiers W. 1983. Improved plasmid vectors with a thermoinducible expression and temperature-regulated runaway replication. Gene 22: 103-113. (Pubitemid 13086968)
136. Robinson HL, Pertmer TM. 2000. DNA vaccines for viral infections: Basic studies and applications. Adv Virus Res 55:1-74.
137. Romano G, Mitcheli P, Pacilio C, Giordano A. 2000. Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18: 19-39. (Pubitemid 30064889)
138. Sahlof EG. 2005. Current issues in the development of a vaccine to prevent human immunodefciency virus: Insights from the society of infectious diseases pharmacists. Pharmacotherapy 25: 741-747.
139. Saldanha AJ, Brauer MJ, Botstein D. 2004. Nutritional homeostasis in batch and steady-state culture of yeast. Mol Biol Cell 15: 4089-4104. (Pubitemid 39122014)
140. Scherer F, Anton M, Schillinger U, Henkel J, Bergemann C, Kruger A, Gansbacher B, Plank C. 2002. Magnetofection: Enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ter 9: 102-109. (Pubitemid 34189525)
141. Segura T, Chung PH, Shea LD. 2005. DNA delivery from hyaluronic acid-collagen hydrogels via a substrate-mediated approach. Biomaterials 26: 1575-1584. (Pubitemid 39441389)
142. Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, Muderspach LI, Cole GA, Crowley-Nowick PA. 2003. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 e7 plasmid DNA. Am J Obstet Gynecol 188: 916-926. (Pubitemid 36530038)
143. Shrof KE, Smith LR, Baine Y, Higgins TJ. 1999. Potential for plasmid DNAs as vaccines for the new millennium. Pharm Sci Technol Today 2: 205-212. (Pubitemid 29238364)
144. Shuler ML, Kargi F. 2002. Bioprocess Engineering Basic Concepts. Prentice Hall, USA.
145. Schmidt T, Friehs K, Flaschel E, Schleef M. 2003. Method for the Isolation of CCC plasmid DNA. U.S. patent 6664078.
146. Smith CR, DePrince RB, Dackor J, Weigl D, Grifth J, Persmark M. 2007. Separation of topological forms of plasmid DNA by anion-exchange HPLC: Shifts in elution order of linear DNA. J Chromatogr B 854: 121-127. (Pubitemid 46962371)
147. Smith J, Zhang YL, Niven R. 1997. Toward development of a non-viral gene therapeutic. Adv Drug Deliv Rev 26: 135-150. (Pubitemid 27289530)
148. Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, Butera ST, Heneine W, Ellenberger DL, Parekh B, Earl PL, Wyatt LS, Moss B, Robinson HL. 2004. Multiprotein HIV type 1 clade B DNA/MVA vaccine: Construction, safety, and immunogenicity in macaques. AIDS Res Hum Retroviruses 20: 654-665. (Pubitemid 38813664)
149. Song MK, Vindurampulle CJ, Capozzo AVE, Ulmer J, Polo JM, Pasetti MF, Barry EM, Levine MM. 2005. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. J Virol 79: 9854-9861. (Pubitemid 41022327)
150. Sousa F, Duarte MF, Prazeres, Queiroz JA. 2008. Afnity chromatography approaches to overcome the challenges of purifying plasmid DNA. Trends Biotechnol 26: 518-525.
151. Sousa F, Prazeres DMF, Queiroz JA. 2009a. Binding and elution strategy for improved performance of arginine afnity chromatography in supercoiled plasmid DNA purifcation. Biomed Chromatogr 23: 160-165.
152. Sousa F, Prazeres DMF, Queiroz JA. 2009b. Improvement of transfection efciency by using supercoiled plasmid DNA purifed with arginine afnity chromatography. J Gene Med 11: 79-88.
153. Stadler J, Lemmens R, Nyhammar T. 2004. Plasmid DNA purifcation. J Gene Med 6: 54-66.
154. Stephan DJ, Yang ZY, San H, Simari RD, Wheeler CJ, Felgner PL, Gordon D, Nabel GJ, Nabel EG. 1996. A new cationic liposome DNA complex enhances the efciency of arterial gene transfer in vivo. Hum Gene Ter 7: 1803-1812. (Pubitemid 26364589)
155. Stern M, Ulrich K, Geddes DM, Alton E. 2003. Poly (d,l-lactide-co- glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo. Gene Ter 10: 1282-1288. (Pubitemid 36987118)
156. Tan L, Kim D-S, Yoo I-K, Choe W-S. 2007b. Harnessing metal ion afnity for the purifcation of plasmid DNA. Chem Eng Sci 62: 5809-5820. (Pubitemid 47484355)
157. Tan L, Lai WB, Lee CT, Kim DS, Choe W-S. 2007a. Diferential interactions of plasmid DNA, RNA and endotoxin with immobilised and free metal ions. J Chromatogr A 1141: 226-234. (Pubitemid 46096970)
158. Tanaka N, Kobayashi H. 2003. Monolithic columns for liquid chromatography. Anal Bioanal Chem 376: 298-301. (Pubitemid 40878024)
159. Tang DC, Devit M, Johnston SA. 1992. Genetic immunization is a simple method for eliciting an immune-response. Nature 356: 152-154.
160. Tatcher DR, Hitchcock A, Hanak JAJ, Varley DL. 1999. Method of Plasmid DNA Production and Purifcation. U. S. patent 5981735.
161. Tierry AR, Vives E, Richard JP, Prevot P, Martinand-Mari C, Robbins I, Lebleu B. 2003. Cellular uptake and intracellular fate of antisense oligonucleotides. Curr Opin Mol Ter 5: 133-138. (Pubitemid 36626453)
162. Tomas M, Klibanov AM. 2003. Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc Natl Acad Sci USA 100: 9138-9143. (Pubitemid 37033896)
163. Turker S, Onur E, Ozer Y. 2004. Nasal route and drug delivery systems. Pharm World Sci 26: 137-142. (Pubitemid 39012580)
164. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, Dewitt CM, Friedman A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiver JW, Montgomery DL, Liu MA. 1993. Heterologous protection
165. United States Food Drug Administration (US FDA). 2007. Considerations for Plasmid DNA Vaccines for Infectious Disease Indications. Ofce of Vaccines Research Review. Rockville, USA.
166. Urthaler J, Ascher C, Wöhrer H, Necina R. 2007. Automated alkaline lysis for industrial scale cGMP production of pharmaceutical grade plasmid-DNA. J Biotech 128: 132-149. (Pubitemid 46001686)
167. Urthaler J, Buchinger W, Necina R. 2005a. Improved downstream process for the production of plasmid DNA for gene therapy. Acta Biochim Pol 52: 703-711. (Pubitemid 41571718)
168. Urthaler J, Buchinger W, Necina R. 2005b. Industrial scale cGMP purifcation of pharmaceutical grade plasmid DNA. Chem Eng Technol 28: 1408-1420. (Pubitemid 41694154)
169. Wagner E, Cotten M, Foisner R, Birnstiel ML. 1991. Transferrin polycation DNA complexes-Te efect of polycations on the structure of the complex and DNA delivery to cells. Proc Natl Acad Sci USA 88: 4255-4259. (Pubitemid 21914518)
170. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. 1993. Gene inoculation generates immune-responses against human immunodefciency virus type 1. Proc Natl Acad Sci USA 90: 4156-4160. (Pubitemid 23134185)
171. Wang H, Chen Y, Li XY, Liu Y. 2007. Synthesis of oligo(ethylenediamino)- beta-cyclodextrin modifed gold nanoparticle as a DNA concentrator. Mol Pharm 4: 189-198. (Pubitemid 46640595)
172. Wang Z, Le G, Shi Y, Wegrzyn G. 2001. Medium design for plasmid DNA production based on stoichiometric model. Process Biochem 36: 1085-1093. (Pubitemid 32506307)
173. Wheeler CJ, Felgner PL, Tsai YJ, Marshall J, Sukhu L, Doh SG, Hartikka J, Nietupski J, Manthorpe M, Nichols M, Plewe M, Liang XW, Norman J, Smith A, Cheng SH. 1996. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci USA 93: 11454-11459. (Pubitemid 26347142)
174. Wieland, JA, Houchin-Ray TL, Shea LD. 2007. Non-viral vector delivery from PEG-hyaluronic acid hydrogels. J Control Release 120: 233-241. (Pubitemid 47058636)
175. Wigglesworth TJ, Teixeira F, Axthelm F, Eisler S, Csaba NS, Merkle HP, Meier W, Diederich F. 2008. Dendronised block copolymers as potential vectors for gene transfection. Org Biomol Chem 6: 1905-1911. (Pubitemid 351693234)
176. Williams JA, Luke J, Langtry S, Anderson S, Hodgson CP, Carnes AE. 2009. Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes. Biotechnol Bioeng 103: 1129-1143.
177. World Health Organization WHO. 2007. Guidelines for assuring the quality and nonclinical safety evaluation of DNA vaccines. World Health Organization. Geneva, Switzerland.
178. Xiang JJ, Tang JQ, Zhu SG, Nie XM, Lu HB, Shen SR, Li XL, Tang K, Zhou M, Li GY. 2003. Ionp-pll: A novel non-viral vector for efcient gene delivery. J Gene Med 5: 803-817. (Pubitemid 40309718)
179. Yao S, Helinsk DR, Toukdarian A. 2007. Localization of the naturally occurring plasmid ColE1 at the cell pole. J Bacteriol 189: 1946-1953. (Pubitemid 46446158)
180. Yoshikawa T, Imazu S, Gao J-Q, Hayashi K, Tsuda Y, Okada N, Tsutsumi Y, Akashit M, Mayumi T, Nakagawa S. 2006. Non-methylated CpG motif packaged into fusogenic liposomes enhance antigen-specifc immunity in mice. Biol Pharm Bull 29: 105-109. (Pubitemid 43036704)
181. Zauner W, Ogris M, Wagner E. 1998. Polylysine-based transfection systems utilizing receptor-mediated delivery. Adv Drug Deliv Rev 30: 97-113. (Pubitemid 28201908)
182. Zhang JP, Wang Q, Smith TR, Hurst WE, Sulpizio T. 2005. Endotoxin removal using a synthetic adsorbent of crystalline calcium silicate hydrate. Biotechnol Prog 21: 1220-1225. (Pubitemid 41099594)